A Case of Daratumumab-Induced Significant Decrease in Donor-Specific HLA Antibodies and Remission Induction Before Haploidentical Stem Cell Transplantation in a Refractory B-ALL Patient

Objective: To explore the method of eliminating donor-specific anti-HLA antibodies (DSA) in haploidentical stem cell transplantation (haplo-SCT). Methods: We present a refractory B-cell acute lymphoblastic leukemia (ALL) patient who had strongly positive DSA, but had no human leukocyte antigen–matched donor. Although CD38 expression on leukemia cells was negative, daratumumab combined with etoposide and venetoclax therapy was chosen for her. Results: She achieved a significant decrease in DSA levels and complete remission on the combination therapy with daratumumab. She then received a haplo-SCT from a daughter as a donor and had a successful engraftment of donor stem cell. In haplo-SCT, strongly positive DSA levels, directed against donor HLA antigens, could be significantly reduced by daratumumab therapy before transplantation and successfully bridge subsequent haplo-SCT. Conclusion: Although CD38 expression is negative in leukemia cells, refractory B-ALL patients may still benefit from combination therapy with daratumumab. We need further clinical observation.

[1]  L. de Leval,et al.  Daratumumab and venetoclax in combination with chemotherapy provide sustained molecular remission in relapsed/refractory CD19, CD20, and CD22 negative acute B lymphoblastic leukemia with KMT2A-AFF1 transcript , 2021, Biomarker Research.

[2]  C. Bredeson,et al.  Nelarabine-containing regimen followed by daratumumab as an effective salvage therapy and bridge to allogeneic hematopoietic stem cell transplantation for primary refractory early T-cell precursor lymphoblastic leukemia , 2021, Leukemia & lymphoma.

[3]  S. Berentsen,et al.  Daratumumab for disabling cold agglutinin disease refractory to B‐cell directed therapy , 2020, American journal of hematology.

[4]  P. Halloran,et al.  CD38 Antibody Daratumumab for the Treatment of Chronic Active Antibody-mediated Kidney Allograft Rejection. , 2020, Transplantation.

[5]  A. Bhattacharyya,et al.  Post‐allogeneic transplant Evans syndrome successfully treated with daratumumab , 2019, British journal of haematology.

[6]  Y. Ofran,et al.  Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell/CD19/CD22-negative acute lymphoblastic leukemia , 2019, Leukemia.

[7]  M. Stegall,et al.  Daratumumab in Sensitized Kidney Transplantation: Potentials and Limitations of Experimental and Clinical Use. , 2019, Journal of the American Society of Nephrology : JASN.

[8]  N. Kröger,et al.  “Worldwide Network for Blood & Marrow Transplantation (WBMT) special article, challenges facing emerging alternate donor registries” , 2019, Bone Marrow Transplantation.

[9]  M. de Lima,et al.  Hematopoietic stem cell transplant with HLA-mismatched grafts: impact of donor, source, conditioning, and graft versus host disease prophylaxis , 2018, Expert review of hematology.

[10]  J. Connors,et al.  Daratumumab for Delayed Red-Cell Engraftment after Allogeneic Transplantation. , 2018, The New England journal of medicine.

[11]  J. Esteve,et al.  Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for , 2018, Bone Marrow Transplantation.

[12]  A. Schulz,et al.  Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation. , 2018, Blood advances.

[13]  G. Ossenkoppele,et al.  CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia , 2018, Haematologica.

[14]  Bo Yang,et al.  Haploidentical versus matched donor stem cell transplantation for patients with hematological malignancies: a systemic review and meta-analysis , 2018, Bone Marrow Transplantation.

[15]  D. Blaise,et al.  The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation , 2018, Bone Marrow Transplantation.

[16]  M. Loh,et al.  Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia. , 2018, Blood.

[17]  D. Gladstone,et al.  HLA donor-specific antibodies in allogeneic hematopoietic stem cell transplantation: challenges and opportunities. , 2017, Hematology. American Society of Hematology. Education Program.

[18]  H. Dombret,et al.  Impact of cytogenetic abnormalities in adults with Ph-negative B-cell precursor acute lymphoblastic leukemia. , 2017, Blood.

[19]  A. Palumbo,et al.  Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. , 2015, The New England journal of medicine.

[20]  P. Thall,et al.  Complement-Binding Donor-Specific Anti-HLA Antibodies and Risk of Primary Graft Failure in Hematopoietic Stem Cell Transplantation. , 2015, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[21]  Yu Wang,et al.  Donor-specific anti-human leukocyte antigen antibodies were associated with primary graft failure after unmanipulated haploidentical blood and marrow transplantation: a prospective study with randomly assigned training and validation sets , 2015, Journal of Hematology & Oncology.

[22]  F. Mancini,et al.  Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts , 2013, Haematologica.

[23]  H. Tamaki,et al.  Risk and prevention of graft failure in patients with preexisting donor-specific HLA antibodies undergoing unmanipulated haploidentical SCT , 2012, Bone Marrow Transplantation.

[24]  E. Shpall,et al.  Lymphocyte recovery predicts outcomes in cord blood and T cell-depleted haploidentical stem cell transplantation. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[25]  E. Shpall,et al.  Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT , 2010, Bone Marrow Transplantation.

[26]  R. Alloway,et al.  Proteasome inhibition for antibody-mediated rejection , 2009, Current opinion in organ transplantation.

[27]  P. Thall,et al.  High Risk of Graft Failure in Patients With Anti-HLA Antibodies Undergoing Haploidentical Stem-Cell Transplantation , 2009, Transplantation.

[28]  J. Baars,et al.  Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison. , 2009, Blood.

[29]  Allen R. Chen,et al.  HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[30]  J. Fallon,et al.  Refractory humoral cardiac allograft rejection successfully treated with a single dose of rituximab. , 2004, Transplantation proceedings.

[31]  O. Cope,et al.  Multiple myeloma. , 1948, The New England journal of medicine.